Abstract:

Objective To investigate the effect of BX⁃912（PDK⁃1 Specific inhibitor）on bone destruction in mice with bone metastases in prostate cancer. Methods In vitro experiment：BX⁃912 was used to intervene in mouse prostate cancer cells（RM⁃1）with increasing concentrations，and the effect of BX⁃912 on the activity of RM⁃1 was detected by Cell Counting Kit⁃8（CCK⁃8），The effect of BX⁃912 on RM⁃1 migration was observed through cell scratch experiment，the effect of BX⁃912 on the independent viability of RM⁃1 was studied by cell cloning experi⁃ ment. In vivo experiment：30 mouse model of prostate cancer bone metastasis were randomly divided into three groups： the control group，the low concentration group，and the high concentration group. Each group was injected with the corresponding concentration of BX⁃912. After 14 days，the tumor was detected by micro⁃CT and weighed after resection. Results CCK⁃8 results showed that the BX⁃912 concentration at 0.625 μmol/L or below had no signifi⁃ cant effect on the activity of RM⁃1（P > 0.05），while the BX⁃912 concentration at 1.25 μmol/L or above had signif⁃ icant inhibitory effect on RM⁃1（P < 0.05）. The scratch test showed that BX⁃912 could significantly inhibit the mi⁃ gration of RM⁃1（P < 0.05）. The clone experiment showed that BX⁃912 significantly inhibited the clone formation rate of RM⁃1（P < 0.05）. BX⁃912 can significantly inhibit the growth of prostate cancer and inhibit the bone destruction in the mouse model of prostate cancer bone metastasis（P < 0.05）. Conclusion BX⁃912 can inhibit the proliferation，migration and cloning of RM⁃1 and ameliorate the bone destruction in the mouse model of bone metastasisin prostate cancer，which has potential significance for the treatment of bone metastasisin prostate cancer.

Key words:

BX?912, prostate cancer, bone metastasis, PDK?1